Cytosorbents Corporation (FRA:HQE1)

Cytosorbents Statistics

Total Valuation

Cytosorbents has a market cap or net worth of EUR 40.52 million. The enterprise value is 57.38 million.

Market Cap	40.52M
Enterprise Value	57.38M

Important Dates

The next estimated earnings date is Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	62.80M
Shares Outstanding	n/a
Shares Change (YoY)	+14.92%
Shares Change (QoQ)	-6.57%
Owned by Insiders (%)	12.55%
Owned by Institutions (%)	26.09%
Float	54.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.29
PB Ratio	5.27
P/TBV Ratio	8.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.56
EV / Sales	1.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.72

Financial Position

The company has a current ratio of 2.11, with a Debt / Equity ratio of 3.01.

Current Ratio	2.11
Quick Ratio	1.48
Debt / Equity	3.01
Debt / EBITDA	n/a
Debt / FCF	-2.71
Interest Coverage	-5.71

Financial Efficiency

Return on equity (ROE) is -93.26% and return on invested capital (ROIC) is -23.42%.

Return on Equity (ROE)	-93.26%
Return on Assets (ROA)	-19.01%
Return on Invested Capital (ROIC)	-23.42%
Return on Capital Employed (ROCE)	-39.93%
Revenue Per Employee	211,528
Profits Per Employee	-58,734
Employee Count	149
Asset Turnover	0.79
Inventory Turnover	2.98

Taxes

Income Tax	-1.78M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.94% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-20.94%
50-Day Moving Average	0.69
200-Day Moving Average	0.82
Relative Strength Index (RSI)	53.86
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	21.03

Income Statement

In the last 12 months, Cytosorbents had revenue of EUR 31.52 million and -8.75 million in losses. Loss per share was -0.15.

Revenue	31.52M
Gross Profit	22.31M
Operating Income	-12.13M
Pretax Income	-10.53M
Net Income	-8.75M
EBITDA	-10.83M
EBIT	-12.13M
Loss Per Share	-0.15

Balance Sheet

The company has 6.42 million in cash and 23.13 million in debt, giving a net cash position of -16.71 million.

Cash & Cash Equivalents	6.42M
Total Debt	23.13M
Net Cash	-16.71M
Net Cash Per Share	n/a
Equity (Book Value)	7.69M
Book Value Per Share	0.12
Working Capital	9.55M

Cash Flow

In the last 12 months, operating cash flow was -8.43 million and capital expenditures -106,830, giving a free cash flow of -8.54 million.

Operating Cash Flow	-8.43M
Capital Expenditures	-106,830
Free Cash Flow	-8.54M
FCF Per Share	n/a

Margins

Gross margin is 70.80%, with operating and profit margins of -38.48% and -27.77%.

Gross Margin	70.80%
Operating Margin	-38.48%
Pretax Margin	-33.42%
Profit Margin	-27.77%
EBITDA Margin	-34.35%
EBIT Margin	-38.48%
FCF Margin	n/a

Dividends & Yields

Cytosorbents does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.92%
Shareholder Yield	-14.92%
Earnings Yield	-21.60%
FCF Yield	-21.07%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cytosorbents has an Altman Z-Score of -8.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.35
Piotroski F-Score	3